IDH2 and astrocytoma (excluding glioblastoma): The main objective of this study was to evaluate progression-free and overall survival (PFS and OS) depending on the extent of resection (EOR) and adjuvant treatment in the largest contemporary cohort of IDH-wt astrocytoma formerly classified as WHO grade II-III.